The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The impact of alloSCT versus blood transfusion & iron chelation on the QoL of patients with TDT
Tsampika Vasileia Kalamara, MD, Aristotle University of Thessaloniki, Thessaloniki, Greece, discusses the findings of a meta-analysis of observational studies investigating the impact of allogeneic stem cell transplantation (alloSCT) versus blood transfusion and iron chelation on the health-related quality of life (QoL) of patients with transfusion-dependent thalassemia (TDT). Patients undergoing alloSCT, both adult and pediatric, demonstrated a superior QoL than those on conventional therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
